<DOC>
	<DOCNO>NCT01099579</DOCNO>
	<brief_summary>The purpose study determine whether atazanavir powder combine ritonavir safe well tolerated produce appropriate drug exposure child ≥3 month &lt; 6 year age .</brief_summary>
	<brief_title>PRINCE : Study Atazanavir ( ATV ) /Ritonavir ( RTV )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>Key Confirmed human immunodeficiency virus ( HIV ) 1 infection diagnose positive virologic test result 2 separate occasion : HIV DNA polymerase chain reaction HIV RNA value ≥1,000 copies/mL Positive HIV enzymelinked immunosorbent assay ≥18 month age , confirmatory Western blot indirect immunoflourescence antibody Infants child either sex , age ≥3 month &lt; 5 year 6 month time first treatment , weight &gt; 5 &lt; 25 kg screen baseline plasma viral load Screening plasma viral load ≥1,000 copies/mL Roche Amplicor® HIV RNA Assay Documented genotypic phenotypic sensitivity screen ATV ( fold change susceptibility &lt; 2.2 ) least 2 nucleoside reverse transcriptase inhibitor ( NRTIs ) approve infant 's country Genotypic sensitivity screen atazanavir ( ATV ) least 2 NRTIs Antiretroviral ( ARV ) treatmentnaive ARV treatmentexperienced . Treatmentexperienced participant define previous exposure ARVs either prior treatment HIV infection postnatal treatment ≥1 ARV prevention mother child transmission . For purpose study , participant expose ARVs utero intrapartum may include study consider treatment naive . ATVnaive participant must genotypic sensitivity screen ATV ( fold change susceptibility &lt; 2.2 ) component local NRTI backbone . The NRTIs must approve pediatric use local country level . Key Experienced participant receive ATV ATV/ritonavir ( RTV ) time prior study enrollment history 2 protease inhibitor failures ARVnaïve experience HIV1 infect patient contraindication study medication syncope Family history QTc interval syndrome , Brugada syndrome , right ventricular dysplasia , correct QTc interval screen &gt; 440 ms One follow cardiac rhythm abnormality document screen electrocardiogram : 1st degree atrioventricular ( AV ) block define protocol , type I 2nd degree AV block awake , type II 2nd degree AV block time , complete AV block time , ageadjusted heart rate &lt; 2nd percentile ) History pancreatitis , peripheral neuropathy , malignancy require systemic therapy , medical condition , opinion investigator , add undue risk trial participation Malabsorption syndrome Presence newly diagnose HIVrelated opportunistic infection medical condition require acute therapy time enrollment Weight &lt; 5 ≥25 kg date first dose ( Day 1 ) . &gt; Grade 2 aspartate transaminase alanine transaminase abnormality Hypersensitivity component study medication formulation ( ATV/RTV , locally prescribe NRTI pediatric indication ) Infants child either gender &lt; 3 month ≥5 year 6 month time first treatment .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>66 Months</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HIV , Pediatric</keyword>
</DOC>